Antigenics Inc. (AGEN)
Oncology Corporate Profile
- Products & Overview
- Recent News
HQ Location
162 Fifth Avenue, Suite 900New York, NY 10010
Company Description
Antigenics is a biotechnology company dedicated to the research and development of technologies and products to treat cancers, infectious disease and autoimmune disorders.
Website: http://www.antigenics.com
Commercial Products
This company does not have any commercial productsPipeline Products
- Brand
- Generic
- Investigational
| Brand / Product | Class | Area of Study | Phase | Partnership |
|---|---|---|---|---|
| Oncophage® / vitespen | immunotherapy | Metastatic Melanoma | III | |
| Oncophage® / vitespen | immunotherapy | Metastatic Renal cell carcinoma (RCC) | III | |
| Oncophage® / vitespen | immunotherapy | Colorectal cancer | II | |
| Oncophage® / vitespen | immunotherapy | Recurrent Glioma | II | |
| Aroplatin™ / liposomal aroplatin | liposomal platinum agent | B-cell Non-Hodgkin's Lymphoma (NHL) | I | |
| Aroplatin™ / liposomal aroplatin | liposomal platinum agent | Colorectal cancer | I | |
| Aroplatin™ / liposomal aroplatin | liposomal platinum agent | Various cancer types | I | |
| Oncophage® / vitespen | immunotherapy | Gastric cancer | I | |
| Oncophage® / vitespen | immunotherapy | Non Small Cell Lung Cancer (NSCLC) | I | |
| Oncophage® / vitespen | immunotherapy | Pancreatic cancer | I | |
| ATRA-IV | liposomal retinoic acid | Melanoma | Preclinical | |
| ATRA-IV | liposomal retinoic acid | Renal cell carcinoma (RCC) | Preclinical |
View additional information on product candidates here »
Recent News Headlines
[Business Wire] - LEXINGTON, Mass.----Antigenics, Inc. today announced that GlaxoSmithKline’s herpes zoster vaccine candidate, which contains Antigenics’ QS-21 Stimulon® adjuvant as a key component, has commenced Phase 3 clinical trials for the prevention of shingles.
[Business Wire] - LEXINGTON, Mass.----Antigenics Inc. reported today its results for the quarter ended June 30, 2010. The company incurred a net loss attributable to common stockholders of $5.2 million, or $0.05 per share, basic and diluted, for the second quarter of 2010, compared with a net loss attributable to common stockholders of $12.3 million, or $0.17 per share, basic and diluted, in the second quarter of 2009.
[GlobeNewswire] - DALLAS -- MicroStockProfit.com announces an investment report featuring Antigenics Inc. . The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.
[AP] - Antigenics reported positive data Tuesday from an early stage clinical therapy trial to treat herpes simplex virus-2, the virus that causes genital herpes.
[Business Wire] - SALT LAKE CITY----Antigenics announced positive results with AG-707, an investigational therapeutic vaccine being developed to treat herpes simplex virus-2 , the virus that causes genital herpes, in infected patients.
[Business Wire] - LEXINGTON, Mass.----Antigenics Inc. will release its second quarter financial results before the market opens on July 29, 2010.
[Business Wire] - LEXINGTON, Mass.----Antigenics Inc. announced that the company received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market LLC on July 20, 2010 indicating that the company is not in compliance with Nasdaq Marketplace Rule 5550 because the bid price for the company’s common stock has closed below the minimum $1.00 per share requirement for 30 consecutive business days.
<summary><![CDATA[WESTCHESTER COUNTY, N.Y. -- Marek Fuchs, TheStreet's media critic, translates Genzyme jargon into English: they wuz' fined!]]></summary><image>http://l.yimg.com/a/p/fi/30/32/94.jpg</image><guid>/yfinance/tscm/strategysession/10766286</guid><link><![CDATA[javascript:void(window.open('http://cosmos.bcst.yahoo.com/up/finance?ch=633473&cl=20024904&lang=','playerWindow','width=793,height=666,scrollbars=no'));]]></link><plink>http://www.thestreet.com/</plink>